CN1233643C - Ramification of a compound of medication as well as preparation method and application - Google Patents
Ramification of a compound of medication as well as preparation method and application Download PDFInfo
- Publication number
- CN1233643C CN1233643C CNB031172199A CN03117219A CN1233643C CN 1233643 C CN1233643 C CN 1233643C CN B031172199 A CNB031172199 A CN B031172199A CN 03117219 A CN03117219 A CN 03117219A CN 1233643 C CN1233643 C CN 1233643C
- Authority
- CN
- China
- Prior art keywords
- application
- preparation
- medicine
- treatment
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention discloses a series of derivatives generated by combining 3-(2-cyclopentyl-2-hydroxy-2-phenylethoxy) quinoclinate and organic acid or inorganic acid, a preparing method thereof and applications thereof in pharmacy. The general formula, i.e., the molecular formula, of the chemical structure of the derivatives is (C20H29NO2)n. R, wherein R represents inorganic acid (radical) or organic acid (radical) except for hydrochloric acid, and n is equal to 1 to 3. The derivatives of the medicine compounds disclosed in the present invention are extensive in application range, particularly applications in preparing anticholinergic medicines for acting on gastrointestinal diseases, ophthalmology diseases, respiratory diseases, diseases of central nervous system, genitourinary renal colic and irritative symptoms of bladders, and have excellent effects on preparing anticholinergic medicines for acting on preanesthetic medication, anti-infection shock and biliary colic. The present invention extends the new applications of the derivatives.
Description
Technical field:
The present invention relates to derivative of a kind of medical compounds and its production and application, particularly relate to by 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine and combine a series of derivative that generates and preparation method thereof and the application in pharmacy with organic acid or mineral acid.
Background technology:
3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine, chemical structural formula is:
Molecular formula is: C
20H
29NO
2
Be combined into Penequine hydrochloride with hydrochloric acid, this compound has been proved being applied to save has effect and clinical efficacy preferably aspect the organophosphate poisoning.The applicant has been found that before this: Penequine hydrochloride has clinical application effect at preparation treatment gastrointestinal tract disease, ophthalmic diseases, respiratory tract disease, central nervous system disease, urogenital tract renal colic and irritative symptoms of bladder in the medicine of preparation anti-septic shock, anti-biliary colic, preanesthetic medication.After further research, 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine combines with other organic acids or mineral acid and can generate a series of derivatives, and it has same or better effect in above-mentioned each side, does not appear in the newspapers.
Summary of the invention:
The objective of the invention is on the basis of existing technology, provide a kind of the combination with organic acid or mineral acid to generate a series of derivatives and the preparation method of this series derivates and the application in pharmacy by 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine.
Concrete technical scheme of the present invention is as follows:
The present invention is combined with organic acid or mineral acid by 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine and generates a series of derivative, and its chemical structure of general formula is:
Molecular formula: (C
20H
29NO
2)
nR
Wherein, R is mineral acid, inorganic acid radical, organic acid or the organic acid beyond the demineralizing acid; N is 1～3.
The preparation method of derivative of the present invention may further comprise the steps:
A, elder generation are dissolved in 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine in the ether, and then combine the formation reaction product with mineral acid diethyl ether solution or organic acid diethyl ether solution; Perhaps directly be that 1%～70% mineral acid is in conjunction with the formation reaction product with 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine and organic acid or concentration;
B, above-mentioned reaction product is dissolved in the ethanol according to 1: 1～5, adds activated carbon decolorizing, the dissolving back adds the ether crystallization fully.
The application of derivative of the present invention in pharmacy comprises: in the application of preparation treatment cholinolytic effect in gastrointestinal tract disease, ophthalmic diseases, respiratory tract disease, central nervous system disease, urogenital tract renal colic and irritative symptoms of bladder medicine, in the application of preparation cholinolytic effect in preanesthetic medication, anti-septic shock, anti-biliary colic medicine.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the gastrointestinal tract disease medicine:
A, the application in preparation treatment peptide ulceration medicine;
B, alleviate GI tension force or move hyperfunction and be applicable to application in intestinal motility that excitation bowel syndrome, guanethidine cause hyperfunction and treatment dysentery and the rectal distention stimulation symptom medicine in preparation;
C, the application in the saliva dysphagia medicine that preparation treatment inhibition salivation, Parkinson's disease hydrostomia, esophagus mechanical obstruction are caused.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the ophthalmic diseases medicine:
A, expand pupil, fundoscopy in preparation, prevent adhesion and treatment iritis, the application in the keratitis medicine;
B, join in the mirror application of regulating in the paralyzer in the preparation optometry.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the respiratory tract disease medicine:
A, the application in preparation alleviation flu and treatment acute rhinitis medicine;
B, the application in preparation relieving asthma medicine.
Of the present inventionly mainly comprise: the application in preparation treatment Parkinson's disease medicine in the application of preparation treatment cholinolytic effect in the central nervous system disease medicine.
The formulation that the prepared derivative of the present invention is made according to conventional pharmaceutical methods comprises injection, tablet, capsule, granule, eye drops, is coated with an agent, nasal drop and sprays.
The administering mode of various preparations of the present invention comprises whole body administration and topical, mainly contains: oral, subcutaneous injection, intramuscular injection, intravenous injection and external application.
The every preparation unit of preparation of the present invention contains this derivative 0.01-10mg. or concentration is 0.025-3%.
The applied range of the derivative of medical compounds of the present invention, particularly in the application of preparation treatment cholinolytic effect in gastrointestinal tract disease, ophthalmic diseases, respiratory tract disease, central nervous system disease, urogenital tract renal colic and irritative symptoms of bladder medicine, have good effect in the application of preparation cholinolytic effect in preanesthetic medication, anti-septic shock, anti-biliary colic medicine, expanded the new purposes of this series derivates.
Embodiment:
Embodiment 1:
The present invention is combined with hydrogen bromide by 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine and generates the Hydrogen bromide amyl ethyl quin ether, and its chemical reaction process is:
The preparation method of Hydrogen bromide amyl ethyl quin ether of the present invention may further comprise the steps:
A, 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine is dissolved in the ether, the dissolving back adds excessive Hydrogen bromide diethyl ether solution fully, makes it separate out solid to reacting completely;
B, the ratio of above-mentioned solid according to 1: 2.5 is dissolved in the ethanolic soln fully, adds property carbon decoloring while still alive, the dissolving back adds anhydrous diethyl ether and separates out crystallization fully.
The application of Hydrogen bromide amyl ethyl quin ether derivative of the present invention in pharmacy comprises: in the application of preparation treatment cholinolytic effect in gastrointestinal tract disease, ophthalmic diseases, respiratory tract disease, central nervous system disease, urogenital tract renal colic and irritative symptoms of bladder medicine, in the application of preparation cholinolytic effect in preanesthetic medication, anti-septic shock, anti-biliary colic medicine.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the gastrointestinal tract disease medicine:
A, the application in preparation treatment peptide ulceration medicine;
B, alleviate GI tension force or move hyperfunction and be applicable to application in intestinal motility that excitation bowel syndrome, guanethidine cause hyperfunction and treatment dysentery and the rectal distention stimulation symptom medicine in preparation;
C, the application in the saliva dysphagia medicine that preparation treatment inhibition salivation, Parkinson's disease hydrostomia, esophagus mechanical obstruction are caused.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the ophthalmic diseases medicine:
A, expand pupil, fundoscopy in preparation, prevent adhesion and treatment iritis, the application in the keratitis medicine;
B, join in the mirror application of regulating in the paralyzer in the preparation optometry.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the respiratory tract disease medicine:
A, the application in preparation alleviation flu and treatment acute rhinitis medicine;
B, the application in preparation relieving asthma medicine.
Of the present inventionly mainly comprise: the application in preparation treatment Parkinson's disease medicine in the application of preparation treatment cholinolytic effect in the central nervous system disease medicine.
The formulation that the prepared Hydrogen bromide amyl ethyl quin ether of the present invention is made according to conventional pharmaceutical methods comprises injection, tablet, capsule, granule, eye drops, is coated with an agent, nasal drop and sprays.
The administering mode of Hydrogen bromide amyl ethyl quin ether preparation of the present invention mainly contains: oral, subcutaneous injection, intramuscular injection, intravenous injection and external application.
The every preparation unit of Hydrogen bromide amyl ethyl quin ether preparation of the present invention contains Hydrogen bromide amyl ethyl quin ether 1mg..
Embodiment 2:
The present invention is combined with acetic acid by 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine and generates the acetic acid amyl ethyl quin ether, and its chemical reaction process is:
The preparation method of acetic acid amyl ethyl quin ether derivative of the present invention may further comprise the steps:
A, with 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine and excessive acetic acid reaction combination;
B, above-mentioned reaction product was dissolved in the ethanolic soln according to 1: 2.5, adds activated carbon decolorizing, the dissolving back adds the anhydrous diethyl ether crystallization fully.
The application of acetic acid amyl ethyl quin ether derivative of the present invention in pharmacy comprises: in the application of preparation treatment cholinolytic effect in gastrointestinal tract disease, ophthalmic diseases, respiratory tract disease, central nervous system disease, urogenital tract renal colic and irritative symptoms of bladder medicine, in the application of preparation cholinolytic effect in preanesthetic medication, anti-septic shock, anti-biliary colic medicine.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the gastrointestinal tract disease medicine:
A, the application in preparation treatment peptide ulceration medicine;
B, alleviate GI tension force or move hyperfunction and be applicable to application in intestinal motility that excitation bowel syndrome, guanethidine cause hyperfunction and treatment dysentery and the rectal distention stimulation symptom medicine in preparation;
C, the application in the saliva dysphagia medicine that preparation treatment inhibition salivation, Parkinson's disease hydrostomia, esophagus mechanical obstruction are caused.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the ophthalmic diseases medicine:
A, expand pupil, fundoscopy in preparation, prevent adhesion and treatment iritis, the application in the keratitis medicine;
B, join in the mirror application of regulating in the paralyzer in the preparation optometry.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the respiratory tract disease medicine:
A, the application in preparation alleviation flu and treatment acute rhinitis medicine;
B, the application in preparation relieving asthma medicine.
Of the present inventionly mainly comprise: the application in preparation treatment Parkinson's disease medicine in the application of preparation treatment cholinolytic effect in the central nervous system disease medicine.
The formulation that the prepared acetic acid amyl ethyl quin ether of the present invention is made according to conventional pharmaceutical methods comprises injection, tablet, capsule, granule, eye drops, is coated with an agent, nasal drop and sprays.
The administering mode of acetic acid amyl ethyl quin ether preparation of the present invention mainly contains: oral, subcutaneous injection, intramuscular injection, intravenous injection, eye, nose external application and spraying.
The every preparation unit of acetic acid amyl ethyl quin ether preparation of the present invention contains acetic acid amyl ethyl quin ether 1mg..
Embodiment 3:
The present invention is that 1: 1 and 2: 1 combine with sulfuric acid and generate hydrogen sulfate amyl ethyl quin ether or sulfuric acid amyl ethyl quin ether respectively by 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine according to mol ratio, and its chemical reaction process is:
A, with 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine according to mol ratio be 1: 1 and 2: 1 respectively with sulfuric acid reaction, obtain corresponding product hydrogen sulfate amyl ethyl quin ether and sulfuric acid amyl ethyl quin ether;
B, above-mentioned reaction product was dissolved in the ethanolic soln according to 1: 2.5 respectively, adds activated carbon decolorizing in case of necessity, the dissolving back adds the ether crystallization fully.
Derivative hydrogen sulfate amyl ethyl quin ether of the present invention and the application of sulfuric acid amyl ethyl quin ether in pharmacy comprise: in the application of preparation treatment cholinolytic effect in gastrointestinal tract disease, ophthalmic diseases, respiratory tract disease, central nervous system disease, urogenital tract renal colic and irritative symptoms of bladder medicine, in the application of preparation cholinolytic effect in preanesthetic medication, anti-septic shock, anti-biliary colic medicine.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the gastrointestinal tract disease medicine:
A, the application in preparation treatment peptide ulceration medicine;
B, alleviate GI tension force or move hyperfunction and be applicable to application in intestinal motility that excitation bowel syndrome, guanethidine cause hyperfunction and treatment dysentery and the rectal distention stimulation symptom medicine in preparation;
C, the application in the saliva dysphagia medicine that preparation treatment inhibition salivation, Parkinson's disease hydrostomia, esophagus mechanical obstruction are caused.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the ophthalmic diseases medicine:
A, expand pupil, fundoscopy in preparation, prevent adhesion and treatment iritis, the application in the keratitis medicine;
B, join in the mirror application of regulating in the paralyzer in the preparation optometry.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the respiratory tract disease medicine:
A, the application in preparation alleviation flu and treatment acute rhinitis medicine;
B, the application in preparation relieving asthma medicine.
Of the present inventionly mainly comprise: the application in preparation treatment Parkinson's disease medicine in the application of preparation treatment cholinolytic effect in the central nervous system disease medicine.
The formulation that prepared hydrogen sulfate amyl ethyl quin ether of the present invention or sulfuric acid amyl ethyl quin ether are made according to conventional pharmaceutical methods comprises injection, tablet, capsule, granule, eye drops, is coated with an agent, nasal drop and sprays.
The administering mode of hydrogen sulfate amyl ethyl quin ether of the present invention or sulfuric acid amyl ethyl quin ether preparation mainly contains: oral, subcutaneous injection, intramuscular injection, intravenous injection and external application.
The sulfur acid hydrogen amyl ethyl quin ether 1mg of the every preparation unit of hydrogen sulfate amyl ethyl quin ether preparation of the present invention; The described sulfuric acid amyl ethyl quin ether preparation sulfur acid amyl ethyl quin ether 0.5mg of every preparation unit.
Embodiment 4:
The present invention is 3: 1,1: 1 and 2: 1 and phosphatase reaction according to mol ratio respectively by 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine, generate corresponding product phosphoric acid amyl ethyl quin ether, biphosphate amyl ethyl quin ether and phosphoric acid hydrogen two amyl ethyl quin ethers, its chemical reaction process is:
A, be 3: 1,1: 1 and 2: 1 and phosphatase reaction according to mol ratio respectively, generate corresponding product phosphoric acid amyl ethyl quin ether, biphosphate amyl ethyl quin ether and phosphoric acid hydrogen two amyl ethyl quin ethers 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine;
B, above-mentioned any one reaction product was dissolved in the ethanolic soln according to 1: 2.5, adds activated carbon decolorizing, the dissolving back adds the anhydrous diethyl ether crystallization fully.
Derivative phosphoric acid amyl ethyl quin ether of the present invention, biphosphate amyl ethyl quin ether and the application of phosphoric acid hydrogen two amyl ethyl quin ethers in pharmacy comprise: in the application of preparation treatment cholinolytic effect in gastrointestinal tract disease, ophthalmic diseases, respiratory tract disease, central nervous system disease, urogenital tract renal colic and irritative symptoms of bladder medicine, in the application of preparation cholinolytic effect in preanesthetic medication, anti-septic shock, anti-biliary colic medicine.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the gastrointestinal tract disease medicine:
A, the application in preparation treatment peptide ulceration medicine;
B, alleviate GI tension force or move hyperfunction and be applicable to application in intestinal motility that excitation bowel syndrome, guanethidine cause hyperfunction and treatment dysentery and the rectal distention stimulation symptom medicine in preparation;
C, the application in the saliva dysphagia medicine that preparation treatment inhibition salivation, Parkinson's disease hydrostomia, esophagus mechanical obstruction are caused.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the ophthalmic diseases medicine:
A, expand pupil, fundoscopy in preparation, prevent adhesion and treatment iritis, the application in the keratitis medicine;
B, join in the mirror application of regulating in the paralyzer in the preparation optometry.
Of the present inventionly comprise in the application of preparation treatment cholinolytic effect in the respiratory tract disease medicine:
A, the application in preparation alleviation flu and treatment acute rhinitis medicine;
B, the application in preparation relieving asthma medicine.
Of the present inventionly mainly comprise: the application in preparation treatment Parkinson's disease medicine in the application of preparation treatment cholinolytic effect in the central nervous system disease medicine.
The formulation that the prepared phosphoric acid amyl ethyl quin ether of the present invention, biphosphate amyl ethyl quin ether or phosphoric acid hydrogen two amyl ethyl quin ethers are made according to conventional pharmaceutical methods comprises injection, tablet, capsule, granule, eye drops, is coated with an agent, nasal drop and sprays.
The administering mode of phosphoric acid amyl ethyl quin ether of the present invention, biphosphate amyl ethyl quin ether or phosphoric acid hydrogen two amyl ethyl quin ether preparations mainly contains: oral, subcutaneous injection, intramuscular injection, intravenous injection and external application.
The phosphoric acid amyl ethyl quin ether preparation of the present invention phosphoric acid amyl ethyl quin ether 0.3mg of every preparation unit, the phosphoric acid dihydro amyl ethyl quin ether 0.5mg of the every preparation unit of described biphosphate amyl ethyl quin ether preparation, the described phosphoric acid hydrogen two amyl ethyl quin ether preparations phosphoric acid hydrogen two amyl ethyl quin ether 1mg of every preparation unit.
The applied range of the derivative of medical compounds of the present invention, particularly in the application of preparation treatment cholinolytic effect in gastrointestinal tract disease, ophthalmic diseases, respiratory tract disease, central nervous system disease, urogenital tract renal colic and irritative symptoms of bladder medicine, have good effect in the application of preparation cholinolytic effect in preanesthetic medication, anti-septic shock, anti-biliary colic medicine, expanded the new purposes of this series derivates.
Claims (7)
1, a kind of derivative of medical compounds generates a series of derivatives by 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine with organic acid or inorganic the combination, and its chemical structure of general formula is:
Molecular formula: (C
20H
29NO
2)
nR
Wherein, R is acetic acid, Hydrogen bromide, sulfuric acid and phosphoric acid; N is 1～3.
2, the preparation method of the derivative of a kind of medical compounds according to claim 1 is characterized in that: may further comprise the steps:
A, elder generation are dissolved in 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine in the ether, and then combine the formation reaction product with mineral acid diethyl ether solution or organic acid diethyl ether solution; Perhaps directly be that 1%～70% mineral acid is in conjunction with the formation reaction product with 3-(2-cyclopentyl-2-hydroxyl-2-phenyl ethoxy) quinuclidine and organic acid or concentration;
B, above-mentioned reaction product is dissolved in the ethanol according to 1: 1～5, adds activated carbon decolorizing, the dissolving back adds the ether crystallization fully.
3, the application of the derivative of a kind of medical compounds according to claim 1, it is characterized in that: in the application of preparation treatment cholinolytic effect in gastrointestinal tract disease, ophthalmic diseases, respiratory tract disease, central nervous system disease, urogenital tract renal colic and irritative symptoms of bladder medicine, in the application of preparation cholinolytic effect in preanesthetic medication, anti-septic shock, anti-biliary colic medicine.
4, the application of the derivative of a kind of medical compounds according to claim 3 is characterized in that: the application of described cholinolytic effect in preparation treatment gastrointestinal tract disease medicine comprises:
A, the application in preparation treatment peptide ulceration medicine;
B, alleviate GI tension force or move hyperfunction and be applicable to application in intestinal motility that excitation bowel syndrome, guanethidine cause hyperfunction and treatment dysentery and the rectal distention stimulation symptom medicine in preparation;
C, the application in the saliva dysphagia medicine that preparation treatment inhibition salivation, Parkinson's disease hydrostomia, esophagus mechanical obstruction are caused.
5, the application of the derivative of a kind of medical compounds according to claim 3 is characterized in that: the application of described cholinolytic effect in preparation treatment ophthalmic diseases medicine comprises:
A, expand pupil, fundoscopy in preparation, prevent adhesion and treatment iritis, the application in the keratitis medicine;
B, join in the mirror application of regulating in the paralyzer in the preparation optometry.
6, the application of the derivative of a kind of medical compounds according to claim 3 is characterized in that: the application of described cholinolytic effect in preparation treatment respiratory tract disease medicine comprises:
A, the application in preparation alleviation flu and treatment acute rhinitis medicine;
B, the application in preparation relieving asthma medicine.
7, the application of the derivative of a kind of medical compounds according to claim 3 is characterized in that: the application of described cholinolytic effect in preparation treatment central nervous system disease medicine mainly comprises: the application in preparation treatment Parkinson's disease medicine.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031172199A CN1233643C (en) | 2003-01-23 | 2003-01-23 | Ramification of a compound of medication as well as preparation method and application |
| PCT/CN2003/000687 WO2004016590A1 (en) | 2002-08-16 | 2003-08-18 | The salts of the quinuclidine derivatives and the preparation and applications thereof |
| AU2003257797A AU2003257797A1 (en) | 2002-08-16 | 2003-08-18 | The salts of the quinuclidine derivatives and the preparation and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031172199A CN1233643C (en) | 2003-01-23 | 2003-01-23 | Ramification of a compound of medication as well as preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1519239A CN1519239A (en) | 2004-08-11 |
| CN1233643C true CN1233643C (en) | 2005-12-28 |
Family
ID=34284638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031172199A Expired - Lifetime CN1233643C (en) | 2002-08-16 | 2003-01-23 | Ramification of a compound of medication as well as preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1233643C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004027555D1 (en) * | 2004-09-15 | 2010-07-15 | Shuqiang Zhao | CHINUCLIDINE COMPOUNDS WITH QUATERNARM AMMONIUM GROUP, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ACETYLCHOLINE BLOCKING AGENTS |
| CN102218061B (en) * | 2011-04-29 | 2012-07-04 | 成都力思特制药股份有限公司 | Application of penehyclidine hydrochloride in preparation of medicine for treating motion sickness |
| CN114306331B (en) * | 2020-10-10 | 2023-07-18 | 远大生命科学(武汉)有限公司 | Use of penehyclidine in the treatment or prevention of vision-damaging ocular disorders |
-
2003
- 2003-01-23 CN CNB031172199A patent/CN1233643C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1519239A (en) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1145619C (en) | 1-4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof | |
| CN1083448C (en) | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (D4) | |
| CN1069098C (en) | Novel imidazole derivative and process for producing the same | |
| CN1195747C (en) | 8,8a-dihydro-indeno [1,2-d] thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents | |
| CN1173959C (en) | 8,8A-dihydro-indeno [1,2-D] thiazole derivatives with a sulphonamido or sulphono substituent in the 2 position, a method for production thereof and use thereof as a medicament | |
| CN101039917A (en) | Process for preparing telmisartan | |
| CN107205961A (en) | The prodrug of phenols TRPV1 activators | |
| CN1020096C (en) | Preparation for imidazoline derivatives | |
| CN1152304A (en) | Substituted benzamidines, their production and their use as medicaments | |
| CN1511828A (en) | Sufonic aniline derivatives and their medicinal use | |
| CN1384827A (en) | Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments | |
| CN1233643C (en) | Ramification of a compound of medication as well as preparation method and application | |
| CN1708482A (en) | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials | |
| CN1908001A (en) | Bile acid derivative and pharmaceutical use thereof | |
| CN1819994A (en) | KAPPA agonists, especialy for the treatment and/or prophylaxis of irritable bowel syndrome | |
| CN1144801C (en) | Vitreous form of know bradykinin antagonist | |
| CN1265091A (en) | Aminoethylphanoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithasis | |
| CN1077790C (en) | Agent for treatment of glaucoma and agent for reducing eye pressure | |
| CN1344263A (en) | Polycyclic 2-aimino-thiazole systems, method for prodn. thereof and medicament contg. said compounds | |
| CN1133626C (en) | Diclofenac coupled derivative and its synthesizing process and inflammation relieving action | |
| CN1946712A (en) | Pyrrolidine derivative | |
| CN1706820A (en) | Prepn and application of N-[2-(aryloxy)ethyl]-2-(arylthio) benzyl amine derivative | |
| CN87105791A (en) | Quinazoline diones and Pyridopyrimidine diketone and preparation method thereof | |
| CN1087901A (en) | New pyridyl-and pyrimidylpiperazine derivatives | |
| CN1882526A (en) | Process for the preparation of voglibose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200518 Address after: 121013 Songshan street, Taihe District, Jinzhou, Liaoning Province, No. 55 Patentee after: SHANGHAI FOCHON PHARMACEUTICAL Co.,Ltd. Address before: 610063 Jinjiang Industrial Development Zone, Chengdu, Sichuan, Jinjiang District Patentee before: CHENGDU LIST PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20051228 |